Emerging Therapies

Immunotherapy with the recently approved anti–PD-1 inhibitor nivolumab prolonged survival in patients with nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy for disease progression with standard platinum-based therapy.
The oncology pipeline remains robust, especially as the industry embraces the promise of immune checkpoint inhibitors.
Although still a relatively new technique, research is moving fast. Data from 3 separate clinical trials presented at ASCO 2015 highlight the progress being made.
Pembrolizumab achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at ASCO 2015.
Pembrolizumab achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at ASCO 2015.
Lenvatinib added to everolimus extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC).
Immunotherapy with nivolumab resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
With new signaling pathways being explored, established drug classes expanding across the tumor spectrum, and immunotherapies investigated across tumor types, the hematology pipeline is abundant. Here are some of the most promising compounds in development presented at ASH 2014
The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors. At ASCO 2014, researchers presented findings for many of these drugs, with immunotherapies leading the way in current drug development in oncology.
Page 3 of 6
Results 21 - 30 of 51
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME